Intangible Assets

XRTX shows no provided evidence of proprietary brands, patents, regulatory exclusivity, or other protected intangibles that would support pricing power versus peers.

The available metrics show deeply negative ROIC/ROCE, which is inconsistent with monetizing unique intangible assets into durable excess returns.

Without filing-based disclosure of defensible IP, customer lock-in, or regulated exclusivity, any intangible advantage appears replicable relative to peers.

Peer comparison is unfavorable because stronger medtech or healthcare peers typically defend margins through patents, clinical data, or reimbursement positions that are not evidenced here.

Switching Costs

No evidence is provided that customers face material technical, clinical, or workflow switching costs that would preserve retention versus peers.

The negative ROIC and zero asset turnover suggest the business is not currently extracting durable value from installed-base lock-in or recurring usage.

If switching costs were meaningful, they would usually support steadier margins and capital returns than the metrics shown here.

Relative to peers with embedded systems, consumables pull-through, or validated integrations, XRTX appears to have materially weaker retention economics.

Network Effects

There is no evidence of a user, data, or ecosystem network effect that compounds value as adoption rises.

The provided metrics do not indicate scale-driven monetization or self-reinforcing demand that would make the platform more valuable than peers over time.

In industries where network effects matter, leaders typically show improving capital efficiency and durable profitability, which is not visible here.

Compared with peer platforms that benefit from multi-sided participation or data flywheels, XRTX shows no observable network-based moat.

Cost Advantage

The negative ROIC/ROCE indicates XRTX is not demonstrating a cost structure advantage that converts into superior returns versus peers.

No evidence is provided of lower manufacturing, sourcing, distribution, or service costs that would allow sustained price competition.

A true cost advantage would usually show up in positive and resilient margins, but the available data point in the opposite direction.

Relative to peers with scale purchasing, process efficiency, or vertically integrated operations, XRTX appears cost-disadvantaged.

Efficient Scale

There is no evidence that XRTX operates in a niche where market size is too small for multiple efficient competitors, which is the core condition for efficient scale.

The extremely weak capital efficiency suggests the company is not capturing scarcity rents from a protected or capacity-constrained market structure.

If efficient scale were present, peers would face structural limits to entry and pricing pressure would be muted, but that is not supported here.

Compared with peers in regulated or capacity-limited segments, XRTX does not appear to benefit from a defensible scale-based barrier.

Overall Score

XRTX shows no provided evidence of durable structural advantage across the five moat drivers, and the negative ROIC/ROCE plus weak efficiency metrics are inconsistent with pricing power, retention, or peer-leading economics.